U.S. Industrial REITs Stock News

People Incorporated recently reported second-quarter 2026 results showing US$436.74 million in sales and a sharp jump in net income to US$506.85 million, while also confirming new CEO Neil Vogel and CFO Timothy Quinn appointments, updating full-year operating income guidance to US$15 million–US$80 million, and completing a multi-year buyback of 15,516,658 shares for US$699.27 million. These developments, alongside activist investor Yakira Capital’s public call to abandon the remaining MGM...

Acushnet Holdings Corp. reported past second-quarter 2026 results with sales of US$819.95 million and net income of US$124.83 million, alongside higher earnings per share versus the prior year. Alongside raising its 2026 sales outlook, completing a long-running US$1.04 billion share buyback and affirming its quarterly dividend highlighted management’s confidence and ongoing capital returns. Next, we’ll examine how Acushnet’s upgraded full-year guidance and solid first-half performance affect...

MSCI Inc. recently launched a consultation on revising its Global Investable Market Indexes to exclude certain “non-operating companies” that behave more like investment funds, using new financial ratio screens focused on operating assets and cash flows. This proposal could reshape index eligibility for niche holdings such as Bitcoin treasury and uranium vehicles, influencing how institutional and ETF investors gain exposure to these themes through MSCI-branded benchmarks. We’ll now examine...

Genco Shipping & Trading (GNK) has become a focal point for investors after Diana Shipping withdrew its takeover offer, citing disagreement with the Genco board over acceptable deal pricing and shareholder value. See our latest analysis for Genco Shipping & Trading. The latest takeover twists sit against a strong run in Genco Shipping & Trading’s stock, with a 42.84% year to date share price return and a 70.51% total shareholder return over one year. Meanwhile, multi year total shareholder...

The recent court decision around de minimis tariffs has quietly reshuffled the playing field for everyday consumer products. Higher costs on low value imports could squeeze some retailers, yet may hand more pricing power to certain domestic manufacturers. For investors, this opens a fresh angle on U.S. made goods exposure that many portfolios may miss. This article walks through three stocks tied to this story and explains why their setup deserves attention now. The stocks outlined below are...

Cencora, Inc. recently reported third-quarter 2026 results, with sales of US$84.75 billion and net income of US$763.52 million, while also declaring a US$0.60 quarterly dividend and amending its credit facilities to expand liquidity and extend maturities. The combination of strong earnings growth across the first nine months of 2026, continued share repurchases totaling 7,950,265 shares for US$2.00 billion, and expanded multi-currency credit capacity highlights how Cencora is using both its...

Prudential Financial (PRU) is back in focus after reporting second quarter 2026 net income of US$985 million and completing a US$498.51 million share repurchase program, a combination many investors watch closely. See our latest analysis for Prudential Financial. Prudential Financial’s recent earnings update and completed US$498.51 million buyback have coincided with rising momentum, with a 90 day share price return of 21.51% and a 1 year total shareholder return of 24.55% from a US$125.13...

Spectrum Brands Holdings (SPB) is back in focus after Q3 2026 results combined a record quarter in Home & Garden with a sizeable intangible asset impairment that pushed the company into a net loss. See our latest analysis for Spectrum Brands Holdings. At a share price of $89.93, Spectrum Brands Holdings has seen a 49.78% year to date share price return and a 63.52% total shareholder return over the past year. This performance suggests momentum has been building as investors weigh the Q3...

Brookfield Wealth Solutions Ltd. reported past second-quarter 2026 results showing revenue rising to US$4,217 million from US$3,037 million a year earlier, while net income fell to US$143 million from US$501 million. For the first half of 2026, revenue edged up to US$5,873 million from US$5,655 million, but results swung from net income of US$175 million to a net loss of US$466 million, even as the company affirmed a quarterly US$0.07 per-share return of capital payable on September 29,...

Champion Homes (SKY) drew attention after first quarter 2026 earnings reported sales of US$710.23 million and net income of US$49.16 million, along with a US$50 million increase in its share repurchase authorization. See our latest analysis for Champion Homes. Champion Homes shares are trading at US$94.53 after a 42.62% 90 day share price return and a 29.19% total shareholder return over the past year, suggesting momentum has strengthened around the mixed earnings and expanded buyback...

In the past quarter, Krystal Biotech, Inc. reported Q2 2026 net income of US$54.77 million, with basic earnings per share from continuing operations of US$1.85, up from US$38.33 million and US$1.33 a year earlier. Over the first half of 2026, net income rose to US$110.70 million and higher per-share earnings underscored the earnings power of Vyjuvek alongside an advancing gene therapy pipeline. We’ll now examine how this stronger profitability profile, anchored by Vyjuvek’s contribution,...

Earlier this month, ICON Investments Six Designated Activity Company priced US$2.15 billion of senior unsecured notes maturing between 2029 and 2036, with guarantees from ICON, to refinance its bridge facility, senior secured term loans and 5.809% senior secured notes due 2027. This refinancing is set to release collateral and subsidiary guarantees tied to ICON's existing debt, effectively shifting the group toward a fully unsecured capital structure. With ICON reshaping its balance sheet...

Viatris (VTRS) is back in focus after raising its 2026 earnings guidance alongside second quarter results that showed higher sales and revenue year on year, as well as a return to net profitability for the first half. See our latest analysis for Viatris. At a share price of US$16.23, Viatris has seen some short term softness with a 1 month share price return of 2.7% and a 3 month share price return of 1.5%. At the same time, the year to date share price return of 30.26% sits alongside a 1...

First Advantage (FA) has drawn investor attention after reporting second quarter 2026 sales of US$448.76 million and net income of US$16.91 million, along with higher full year revenue guidance supported by broad-based customer demand. See our latest analysis for First Advantage. At a share price of US$21.58, First Advantage has had a 90 day share price return of 45.12% and a year to date share price return of 51.44%. The 1 year total shareholder return of 30.95% points to momentum that has...

TKO Group Holdings (TKO) drew fresh attention after releasing second quarter 2026 results, raising full year revenue guidance, and updating investors on progress with its multi year share repurchase program. See our latest analysis for TKO Group Holdings. The share price reaction has been positive in the short term, with a 7 day share price return of 7.89% and a 30 day gain of 8.39%, while the year to date share price return is still down 2.74%. Over longer horizons, total shareholder return...

Freshpet, Inc. reported its second-quarter 2026 results in early August, with sales of US$305.59 million and net income of US$19.49 million, alongside higher earnings per share versus the prior year period. Management paired these results with a higher 2026 net sales growth outlook and confirmed expectations for 2027 sales to outpace overall category expansion, underlining confidence in its growth trajectory. We’ll now examine how Freshpet’s raised 2026 net sales growth guidance reshapes the...

Inhibrx Biosciences, Inc. reported second-quarter 2026 results, with net loss widening to US$36.65 million and basic loss per share from continuing operations at US$2.34, while first-half losses were broadly similar to the prior year. Alongside these figures, the company highlighted FDA acceptance of its biologics license application for ozekibart in conventional chondrosarcoma, setting a PDUFA goal date of April 14, 2027, and pointed to upcoming Phase 2 data for INBRX-106 in head and neck...

Simpson Manufacturing stock has delivered a strong 79.4% return over the past 5 years, yet current checks suggest the shares now sit close to their intrinsic value rather than offering a clear bargain. The Discounted Cash Flow (DCF) intrinsic value estimate aligns with this picture of a stock that looks roughly fairly priced at around US$193.78. Over 5 years, Simpson Manufacturing has returned 79.4%, which points to a solid outcome for long-term shareholders, even if the valuation now looks...

In early August 2026, Exelixis reported past second-quarter results showing revenue of US$628.69 million and net income of US$212.05 million, while slightly trimming its full-year 2026 revenue outlook to US$2.50 billion–US$2.55 billion and filing a US$112 million employee stock plan-related shelf registration. Alongside these financial updates, Exelixis highlighted continued progress of its oncology pipeline, including zanzalintinib as a potential second franchise, reinforcing its effort to...

Vaxcyte, Inc. recently reported second-quarter 2026 results showing a wider net loss of US$284.3 million and higher basic loss per share, while also updating investors on the progress of its vaccine pipeline. Alongside the larger first-half loss of US$604.92 million, management highlighted full enrollment of three pivotal VAX-31 adult Phase 3 trials and early-stage progress for VAX-A1 against Group A Streptococcus, underscoring the company’s heavy investment in late- and early-stage vaccine...

Perrigo Company plc recently reported its second-quarter 2026 results, with sales of US$1,022.8 million and net income of US$74.5 million, and reaffirmed full-year 2026 guidance calling for an All In net sales decline of between 5.5% and 1.5%. The quarter marked a shift from a net loss a year earlier to positive earnings per share, even as both quarterly and year-to-date sales fell compared with 2025 and the company remained loss-making over the first half. We’ll now examine how Perrigo’s...

Fidelity National Financial recently reported past second-quarter 2026 results, with revenue of US$4,051 million and net income of US$288 million, alongside a quarterly dividend declaration of US$0.52 per share payable on September 30, 2026. The combination of stronger earnings driven by commercial transaction activity, disciplined cost control, and ongoing share repurchases highlights management’s emphasis on both operational efficiency and direct capital returns to shareholders. Next,...

Janus Living (JAN) has completed a $464 million follow on equity offering of 16,000,000 Class A 1 common shares at $29 each, reflecting a discount of $1.0875 per share. See our latest analysis for Janus Living. Janus Living shares have gained momentum in recent months, with a 14.8% 90 day share price return and 29.8% year to date share price return, as investors respond to stronger earnings, raised 2026 guidance and the completed equity raise. If this kind of activity has your attention, it...

In August 2026, USA TODAY Sports launched USA TODAY Sports Fantasy, a US$39.99-per-year fantasy football subscription platform, while Golfweek partnered with REMAX Golf Lifestyles to create a free golf real estate and lifestyle hub for its 2 million monthly users. Together, these moves show USA TODAY expanding beyond traditional news into subscription-based fantasy tools and niche lifestyle experiences that deepen audience engagement. Next, we’ll examine how the new USA TODAY Sports Fantasy...